Privia Health Exceeds 2025 Guidance, Projects Strong 2026 Growth with ~20% Adjusted EBITDA Increase
PRVA sits 19% above its 52-week low of $18.77 on elevated volume (2.0× avg).
Summary
Privia Health Group announced strong fourth quarter and full-year 2025 financial results, exceeding its own guidance ranges for the year, and provided an optimistic outlook for 2026 with projected double-digit Adjusted EBITDA growth.
Key Events · Earnings and Guidance · PRVA
-
Full-Year 2025 Results Exceed Guidance
Privia Health reported full-year 2025 financial and operating metrics at or above the high end of its guidance ranges, including a 22.3% increase in total revenue to $2.12 billion and a 38.8% rise in Adjusted EBITDA to $125.5 million.
-
Significant Profitability and Cash Flow Growth
Net income for full-year 2025 surged by 59.3% to $22.9 million, while net cash provided by operating activities grew 49.5% to $163.4 million.
-
Positive 2026 Financial Outlook
The company issued 2026 guidance projecting continued growth, with Adjusted EBITDA expected to increase by approximately 15.5% to 23.5% (midpoint ~20%) to a range of $145 million to $155 million.
-
Robust Balance Sheet
Privia Health ended 2025 with a strong cash balance of $479.7 million and no debt, with expectations to reach approximately $600 million in cash by the end of 2026.
Analysis · PRVA · Industrial Applications And Services
Privia Health's latest earnings report signals robust operational and financial health, significantly outperforming its own high-end guidance for 2025 across key metrics like Adjusted EBITDA, net income, and attributed lives. This strong performance, coupled with a healthy balance sheet featuring substantial cash and no debt, provides a solid foundation for future growth. The positive 2026 guidance, projecting continued double-digit Adjusted EBITDA growth, reinforces investor confidence in the company's ability to execute its strategy and expand its physician enablement platform. Investors should view this report as a strong indicator of sustained operational momentum and financial stability.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRVA was trading at $22.41 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $18.77 to $26.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.